ClinicalTrials.gg
RecruitingNCT06250686BENITAUpdated Feb 9, 2024

Exercise and Nutrition Intervention in Ovarian Cancer

An interventional study of combined exercise and nutrition intervention in Ovarian Cancer, Malnutrition and Muscle Wasting, sponsored by Universitätsklinikum Hamburg-Eppendorf. Recruiting at 7 sites in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-09.

Sponsored by Universitätsklinikum Hamburg-Eppendorf · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
185
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 189 studies in Ovarian Neoplasms with a site in Germany — 34 open to participants now, 54 under way, 19 of them phase 3. Ovarian Neoplasms · Germany.

Planned enrollment
98th of 163
185 · median 250
Started
2024
with 9 others
No phase
16 of 189
2 open now
Primary completion
2025-07
later than 9 of 53 live
Registered
168th of 189
by date

Among the 189 studies in Ovarian Neoplasms with a site in Germany, this one is the 98th largest by planned enrollment of the 163 interventional ones that give a count, is one of 10 that started in 2024, is one of 16 with no phase, reaches primary completion later than 9 of the 53 other live ones, and was the 168th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

34 of the 189 studies in Ovarian Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Ovarian Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

The objective of this multicenter randomized controlled trial is to compare a 6-month exercise and nutrition intervention (intervention group, IG) aimed at maintaining or improving physical functioning and quality of life with usual care (control group, CG) in ovarian cancer patients.

The main question it aims to answer is:

  • Can an exercise and nutrition program improve physical performance during and after active treatment for ovarian cancer?

Participants of the IG will undergo:

  • Weeks 1-18: approximately 15-30 minutes of daily exercise (cardio, resistance, and balance exercises); nutritional counseling focusing on malnutrition (protein-energy malnutrition).
  • Weeks 19-25: More intense daily training; nutritional counseling focusing on the Mediterranean diet.

The study design includes 3 survey time points:

  • Baseline: After surgery and before starting chemotherapy
  • T1: After chemotherapy (week 19)
  • T2: After intervention (week 26)

The primary outcome is:

  • 6-minute walk test, 6 months after enrollment (T2)
03

Conditions studied

  • Ovarian Cancer
  • Malnutrition
  • Muscle Wasting
  • Fatigue
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with FIGO II-IV stage ovarian, fallopian tube, or peritoneal carcinoma
  • Patients must be treated with surgery and chemotherapy
  • Patients receiving or neoadjuvant chemotherapy but not yet started

Exclusion criteria

Exclusion Criteria:

  • Patients with an (ECOG) performance status greater than 2
  • Patients with inadequate German language skills
  • Patients with physical or mental impairments that make it impossible to perform the training programs or study procedures
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
185 participants (estimated)

Study arms

  • No intervention
    Control group

    usual care

  • Experimental
    Intervention

    6 month exercise and nutrition intervention

    Behavioral: combined exercise and nutrition intervention

Interventions

  • Behavioralcombined exercise and nutrition intervention

    Patients will be instructed on how to use the Physitrack app. At the start of chemotherapy, patients will be contacted by physiotherapists and dietitians from the University Medical Center Hamburg-Eppendorf either via video call using the app or by phone to discuss the first week's program. Patients can either complete the exercise program at home using the app or receive printed exercise plans in the mail to be completed with the physical therapist of their choice. The exercise program is adjusted weekly until week 9. After week 10, adjustments are made every two weeks. For each program, patients receive a 30-minute counseling session to discuss the exercises. The 30-minute nutritional counseling session occurs every two weeks. For patients receiving neoadjuvant chemotherapy, the exercise program is interrupted for the time of surgery and the two-week recovery period and resumed when chemotherapy is resumed.

06

What researchers measure

Primary outcomes

  1. 6 Minute Walk Test (distance in metre)

    Sub-maximal exercise test used to assess aerobic capacity and endurance

    Time frame: Change in the total distance from T2 (6 months after enrollment) to baseline as target

Secondary outcomes

  1. 6 Minute Walk Test (distance in metre)

    Sub-maximal exercise test used to assess aerobic capacity and endurance

    Time frame: Change in the total distance from T1 (end of chemotherapy, approx. week 18-19) to baseline as target

  2. Global physical activity questionnaire (GPAQ)

    Physical activity in minutes per day, MET minutes per week

    Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

  3. Assessment of body composition using bioelectrical impedance analysis (BIA)

    Bioelectrical impedance analyzers use an alternating electric current to measure the two components of bioelectrical impedance in the human body, resistance r and reactance Xc. In electrophysiological terms, resistance (per unit volume) correlates negatively with the amount of body fluid (body water and fat-free mass (FFM)) through which the current flows, while reactance correlates positively with the mass of body cells. The magnitude of Xc in relation to R is expressed as the phase angle (PA). From the measured R and Xc values and other subject data, additional indicators of body composition (e.g., total body water, fat-free mass, and fat mass) can be estimated using specific prediction equations based on modeling assumptions that are generally population-, age-, sex-, fat-, and disease-specific.

    Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

  4. Grip force dynamometer

    Hand gripping force (kg)

    Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

  5. Polyneuropathy; item derived from EORTC CIPN20 (Item 9)

    Problems standing or walking, because can't longer feel the ground under feet

    Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

  6. Patient Health Questionnaire-9 (PHQ-9)

    Depression screening

    Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

  7. Generalized Anxiety Disorder using GAD-2

    Anxiety

    Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

  8. Adherence to a Mediterranean diet (MEDAS)

    Adherence to a Mediterranean diet is assessed using the 14-item Mediterranean Diet Adherence Screener (MEDAS).

    Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

  9. EORTC QLQ-C30

    Quality of life (multidimensional) across 10 subscales

    Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

  10. EORTC OV-28

    Quality of life (multidimensional) focusing on ovarian cancer across 7 subscales

    Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

  11. EORT FA-12

    Quality of life (multidimensional) focusing on fatigue

    Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

  12. Nutritional Risk Screening (NRS 2002)

    Malnutrition risk

    Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

  13. Brief Social Support Scale (BS6)

    Social support (tangible support, emotional-informational support)

    Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

  14. Patient Activation Measure (PAM-13)

    Patient Activation Measure

    Time frame: Baseline, T1: After chemotherapy (week 19), T2: (6 months after enrollment) to baseline which is after intervention (week 26))

07

Study locations

3 of 7 sites recruiting
  • Charité Universitätsmedizin Berlin
    Berlin, 13353, Germany
    Recruiting
    • Jalid Sehouli, Prof. Dr. · Contact
    • Jalid Sehouli, Prof. Dr. · Principal investigator
  • Universitätskrebszentrum Dresden
    Dresden, 01307, Germany
    Not yet recruiting
    • Pauline Wimberger, Prof. Dr. · Contact
    • Pauline Wimberger, Prof. Dr. · Principal investigator
  • Evang. Klinik Essen-Mitte
    Essen, 45136, Germany
    Recruiting
    • Philipp Harter, PD Dr. · Contact
    • Philipp Harter, PD Dr. · Principal investigator
  • Universitätsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
    Recruiting
    • Barbara Schmalfeldt, Prof. Dr. · Contact
    • Barbara Schmalfeldt, Prof. Dr. · Sub investigator
  • Universitätsklinikum Schleswig-Holstein
    Kiel, 24105, Germany
    Not yet recruiting
    • Nicolai Maass, Prof. Dr. · Contact
    • Nicolai Maass, Prof. Dr. · Principal investigator
  • Klinikum rechts der Isar der Technischen Universität München Ismaniger Straße 22
    München, 81675, Germany
    Not yet recruiting
    • Marion Kiechle, Prof. Dr. · Contact
    • Marion Kiechle, Prof. Dr. · Principal investigator
  • Universitätsklinikum Tübingen
    Tübingen, 72076, Germany
    Not yet recruiting
    • Stefan Kommoss, Prof. Dr. · Contact
    • Stefan Kommoss, Prof. Dr. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — The study protocol will be published in a peer-reviewed journal at the outset. The Statistical Analysis Plan (SAP), Informed Consent Form (ICF), and analysis code will be provided upon request, if available at the time of request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jul 2025, 18 months after the start.

Of 284 non-industry interventional studies with no phase under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 18 months is below that.

Counting every sponsor, half of 295 studies reached it within 46 months; a quarter within 23 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2023
First posted
Feb 9, 2024
StartActual
Jan 10, 2024
Primary completionEst.
Jul 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Feb 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06250686
Responsible party
Sponsor
First posted
Feb 9, 2024
Start date
Jan 10, 2024
Primary completion
Jul 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Feb 9, 2024

Study contacts

Holger Schulz, Prof. Dr.
Contact
schulz@uke.de
+49 (0) 40 7410 56806
Tabea Maurer, Dr.
Contact
ta.maurer@uke.de
+49 (0) 40 7410 50800
Holger Schulz, Prof. Dr.
principal investigator · Universitätsklinikum Hamburg-Eppendorf

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion